Clinical Trial

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment
Protocol Amendment History 2 changes
notable Enrollment reduced: 200 -> 160 participants 2026-05-27
notable Trial sites expanded: 7 -> 17 locations 2026-05-27
Trial Details
NCT Number NCT07079475
Lead Sponsor Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 160 participants
Start Date 2025-07-30
Primary Completion 2028-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-26